From the Journals

COVID-19 antibody response not reduced with diabetes


 

A version of this article originally appeared on Medscape.com.

Pages

Recommended Reading

Does metformin reduce risk for death in COVID-19?
The Hospitalist
EMPEROR-Reduced: Empagliflozin’s HFrEF benefit solidifies class effects
The Hospitalist
DAPA-CKD: SGLT2 inhibitor benefit extends to chronic kidney disease without diabetes
The Hospitalist
Gut bacteria linked to cardiovascular, other health conditions
The Hospitalist
DAPA-CKD resets eGFR floor for safe SGLT2 inhibitor use
The Hospitalist
AHA scientific statement highlights cardiorenal benefit of new diabetes drugs
The Hospitalist
Dapagliflozin’s CKD performance sends heart failure messages
The Hospitalist
EMPEROR-Reduced: Empagliflozin’s HFrEF benefit holds steady on top of sacubitril/valsartan
The Hospitalist
Empagliflozin cut PA pressures in heart failure patients
The Hospitalist
Entresto halves renal events in preserved EF heart failure patients
The Hospitalist
   Comments ()